Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 15/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 14/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1412184 | 0.84 | ADORA3 (0.44) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL1412185 | 0.84 | ADORA3 (0.44) | LMNATP53ALDH1A1MAPTTDP1 | |
| Acetic Acid SCHEMBL243164 | 0.84 | ADORA2A (0.44) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL242860 | 0.84 | ADORA2A (0.45) | ADORA2AADORA3 | |
| SCHEMBL242859 | 0.84 | ADORA2A (0.45) | ADORA2AADORA3 | |
| SCHEMBL241874 | 0.83 | ADORA2A (0.58) | ADORA2AADORA3ADORA1 | |
| SCHEMBL243880 | 0.82 | LMNA (0.49) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL293365 | 0.81 | ADORA2A (0.57) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL1412247 | 0.81 | ADORA2A (0.57) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL1833924 | 0.81 | ADORA2A (0.57) | LMNATP53ALDH1A1MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2013211-B1 | PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2012-03-14 | — | — | EP | disclosed |
| US-20120004212-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2012-01-05 | — | — | US | disclosed |
| US-20120004247-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2012-01-05 | — | — | US | disclosed |
| EP-2322525-A1 | Purine derivatives for use as adenosin A2A receptor agonists | Novartis AG (CH) | 2011-05-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004212-A1 | ORGANIC COMPOUNDS | CYP3A43, SLCO1B3, CYP2C19 | LMNA 3993/4885TP53 969/4885ALDH1A1 166/4885 |
| US-20120004247-A1 | ORGANIC COMPOUNDS | CYP3A43, SLCO1B3, CYP2C19 | LMNA 3993/4885TP53 969/4885ALDH1A1 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.